Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    PROSPECT II
Previous Study | Return to List | Next Study

PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. (P2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02171065
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : August 19, 2020
Sponsor:
Collaborators:
Abbott Medical Devices
InfraReDx
The Medicines Company
Information provided by (Responsible Party):
Uppsala University

Brief Summary:

The present study has two components, an overall prospective observational study using multimodality imaging (PROSPECT II) that will examine the natural history of patients with unstable atherosclerotic coronary artery disease with the specific goal to establish the utility of low-risk intracoronary imaging modalities, IVUS and NIRS, to identify plaques prone to future rupture and clinical events. The randomized PROSPECT ABSORB substudy will examine whether treatment of vulnerable plaques with the Absorb BVS plus GDMT safely increases the MLA at 24 months compared with GDMT alone.

The cutoff for inclusion in PROSPECT ABSORB will be a site-determined PB ≥65% (rather than the 70% cutoff identified in the original PROSPECT analysis (Stone et al., NEJM, 2011(5)) to account for an observed tendency for sites to underestimate plaque burden during acute treatment of ACS patients. Nonetheless, in PROSPECT, a core laboratory determined PB ≥65% was also associated with a high (7.0%) rate of MACE during 3-year follow-up, a rate which may be reduced with a bioresorbable scaffold.


Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome (ACS) Device: sham Device: ABSORB BVS Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 902 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients With ACS- PROSPECT II (Natural History Study), Combined With a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)
Actual Study Start Date : June 2014
Actual Primary Completion Date : May 2020
Actual Study Completion Date : May 2020

Arm Intervention/treatment
Sham Comparator: Guideline Directed Medical Therapy
Guideline Directed Medical Therapy
Device: sham
Active Comparator: ABSORB BVS + Guideline Directed Medical Therapy
ABSORB BVS + Guideline Directed Medical Therapy
Device: ABSORB BVS



Primary Outcome Measures :
  1. Prospect II: Patient level non-culprit lesion related Non-Culprit Major Adverse Cardiac Event (NC-MACE) through 2 years adjudicated to an originally untreated non-culprit lesion [ Time Frame: 2 years ]
    Patient-level rate of NCL-related MACE (NC-MACE) evaluated at the longest follow-up available, assessed at the time when the last patient enrolled reaches at least 24 months. NC-MACE is defined as an event arising from an originally untreated NCL consisting of the composite of 1) cardiac death, 2) MI, 3) unstable angina, or 4) progressive angina or anginal equivalent symptoms either 4a) requiring revascularization by CABG or PCI, and/or 4b) with ACL-confirmed rapid lesion progression.(NC-MACE) at the time when the last patient enrolled reaches at least 24-month follow-up defined as an event arising from an originally untreated NCL consisting of the composite of 1) cardiac death, 2) myocardial infarction, 3) unstable angina, or 4) progressive angina or anginal equivalent symptoms either 4a) requiring revascularization by CABG or PCI, and/or 4b) with ACL-confirmed rapid lesion progression.

  2. Prospect Absorb: The minimum luminal area (MLA) at the randomized non-culprit lesion site in patients treated with the ABSORB BVS + GDMT compared to GDMT only measured at 25 months [ Time Frame: 25 month ]
    The MLA at the randomized NCL site in patients treated with Absorb BVS + GDMT compared to GDMT only as measured at 25 months.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

PROSPECT II

Inclusion Criteria:

  1. Troponin positive ACS (STEMI >12 h or NSTEMI) occurring within the prior 4 weeks of enrollment, with symptoms consistent with acute ischemia lasting >10 minutes, intended for angiography and Percutaneous Coronary Intervention (PCI) if appropriate.
  2. Patient must have one-vessel, two-vessel or three-vessel disease in native coronary arteries requiring PCI.
  3. Successful PCI

Exclusion Criteria:

  1. Known estimated creatinine clearance <30 ml/min.
  2. Cardiogenic shock, decompensated hypotension or heart failure requiring intubation, inotropes, intravenous diuretics or a hemodynamic support device.
  3. Patient has a known hypersensitivity, allergy or contraindication to any of the following: aspirin, both heparin and bivalirudin, all 3 of clopidogrel, prasugrel and ticagrelor, or to contrast that cannot be adequately pre-medicated.
  4. Refractory ventricular arrhythmias (e.g. ventricular tachycardia or fibrillation) requiring either intravenous pharmacologic treatment or defibrillation during the index PCI procedure.
  5. Persistent acute conduction system disease requiring temporary pacemaker insertion during the index PCI procedure.
  6. Prior Coronary Artery Bypass Graft (CABG) at any time or planned CABG.
  7. PCI is required of the left main coronary artery, or a left main stenosis is present with a visually estimated angiographic Diameter Stenosis (DS) of >30%.
  8. Angiographic evidence of severe calcification and/or marked tortuosity of the target (culprit) or a non-culprit vessel is present that would preclude the feasibility of safe imaging of at least the proximal 6 cm of all vessels.
  9. The presence of a chronic total occlusion of a major epicardial coronary vessel that is not successfully recanalized during the PCI procedure, and thus would preclude intravascular imaging.

PROSPECT ABSORB

Inclusion Criteria:

if one or more eligible lesions are identified which meet all of the following angiographic criteria:

  1. The lesion is a de novo lesion (may be located in either the target or non-target vessel)
  2. The lesion has an angiographic diameter stenosis <70%, and is not intended for revascularization based on angiographic criteria and Fractional Flow Reserve/Instantaneous wave-free ratio (FFR/iFR).

    Note: FFR/iFR should be performed on all noncritical lesions of greater than 40% visually estimated angiographic stenosis that are candidates for the ABSORB substudy.

  3. The lesion has a site-determined IVUS plaque burden in at least one frame ≥65%. Note: Such a lesion may or may not be angiographically evident; i.e. the visually estimated angiographic diameter stenosis may range between 0% - <70%.
  4. The reference vessel diameter of an eligible lesion is ≥2.5 mm - ≤4.0 mm (visually estimated) capable of being treated with a 2.5 mm, 3.0 mm, or 3.5 mm diameter BVS.
  5. The lesion length of an eligible lesion is ≤50 mm (visually estimated), capable of being treated by no more than two BVS (maximum length of each BVS 28 mm), allowing for 2 mm BVS overlap and 2 mm of "normal" reference segment treatment at each edge.
  6. The lesion must be at least 10 mm from a previously implanted stent/scaffold and an intervening 10 mm segment must not have plaque burden (PB) >50%
  7. A bifurcation lesion may be enrolled only if the side branch is a) ≤2.5 mm in reference vessel diameter, AND b) has either no lesion requiring treatment, or atherosclerotic disease limited to within 5 mm of its origin from the parent vessel such that the operator believes that the side branch can be successfully treated with balloon angioplasty only (without a stent). If a stent subsequently becomes necessary, only a metallic drug-eluting stent (DES; XIENCE strongly recommended) may be used to treat the side branch with a T-stent technique.
  8. Randomization must occur immediately after the 3-vessel imaging run in the PROSPECT II protocol. If the patient randomizes to BVS, BVS placement must be performed immediately after randomization.

Exclusion Criteria:

  1. The randomized lesion cannot be within 10 mm of a lesion previously treated by PCI .
  2. The randomized lesion may not be in the left main coronary artery.
  3. The randomized lesion may not be an ostial Left Anterior Descending Coronary Artery (LAD) or ostial Left Circumflex Coronary Artery (LCX) lesion (defined as within 3 mm of the left main coronary artery).
  4. The randomized lesion may not be an ostial Right Coronary Artery (RCA) lesion (defined as within 3 mm of the aorto-ostium).
  5. Angiographic evidence of severe calcification and/or marked tortuosity of the target vessel and/or lesion intended for randomization is present that would make it unlikely that the BVS could be advanced to or across the lesion or be adequately expanded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02171065


Locations
Layout table for location information
Sweden
David Erlinge
Lund, Sweden, 221 85
Sponsors and Collaborators
Uppsala University
Abbott Medical Devices
InfraReDx
The Medicines Company
Investigators
Layout table for investigator information
Study Chair: David Erlinge, MD, PhD Lund University
Layout table for additonal information
Responsible Party: Uppsala University
ClinicalTrials.gov Identifier: NCT02171065    
Other Study ID Numbers: PROSPECT II & PROSPECT ABSORB
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 2020
Keywords provided by Uppsala University:
NIRS/IVUS
multimodality imaging
PROSPECT
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases